Microbix Biosystems Inc. provided earnings guidance for the full-year fiscal 2024. The company expects to generate meaningful sales and net earnings growth across full-year fiscal 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.34 CAD | +3.03% | 0.00% | -12.82% |
Apr. 25 | Microbix to Present New Lab Accreditation Program at European Congress on Clinical Microbiology | MT |
Apr. 25 | Microbix Collaborator Introduces New Lab Accreditation Program | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.82% | 33.19M | |
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |
- Stock Market
- Equities
- MBX Stock
- News Microbix Biosystems Inc.
- Microbix Biosystems Inc. Provides Earnings Guidance for the Full-Year Fiscal 2024